998 related articles for article (PubMed ID: 36951829)
21. Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
Ioannou GN; Berry K; Rajeevan N; Li Y; Mutalik P; Yan L; Bui D; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Bajema KL
Ann Intern Med; 2023 Nov; 176(11):1486-1497. PubMed ID: 37903369
[TBL] [Abstract][Full Text] [Related]
22. Early Adoption of Anti-SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022.
Bajema KL; Wang XQ; Hynes DM; Rowneki M; Hickok A; Cunningham F; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Viglianti EM; Streja E; Yan L; Aslan M; Huang GD; Ioannou GN
JAMA Netw Open; 2022 Nov; 5(11):e2241434. PubMed ID: 36367727
[TBL] [Abstract][Full Text] [Related]
23. Risks and burdens of incident diabetes in long COVID: a cohort study.
Xie Y; Al-Aly Z
Lancet Diabetes Endocrinol; 2022 May; 10(5):311-321. PubMed ID: 35325624
[TBL] [Abstract][Full Text] [Related]
24. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
26. Rates and Factors Associated With Documentation of Diagnostic Codes for Long COVID in the National Veterans Affairs Health Care System.
Ioannou GN; Baraff A; Fox A; Shahoumian T; Hickok A; O'Hare AM; Bohnert ASB; Boyko EJ; Maciejewski ML; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM
JAMA Netw Open; 2022 Jul; 5(7):e2224359. PubMed ID: 35904783
[TBL] [Abstract][Full Text] [Related]
27. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
[TBL] [Abstract][Full Text] [Related]
29. Health Care Utilization in the 6 Months Following SARS-CoV-2 Infection.
Tartof SY; Malden DE; Liu IA; Sy LS; Lewin BJ; Williams JTB; Hambidge SJ; Alpern JD; Daley MF; Nelson JC; McClure D; Zerbo O; Henninger ML; Fuller C; Weintraub E; Saydah S; Qian L
JAMA Netw Open; 2022 Aug; 5(8):e2225657. PubMed ID: 35960522
[TBL] [Abstract][Full Text] [Related]
30. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
32. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
[TBL] [Abstract][Full Text] [Related]
33. Long COVID after breakthrough SARS-CoV-2 infection.
Al-Aly Z; Bowe B; Xie Y
Nat Med; 2022 Jul; 28(7):1461-1467. PubMed ID: 35614233
[TBL] [Abstract][Full Text] [Related]
34. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
[TBL] [Abstract][Full Text] [Related]
35. Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness.
Wisk LE; Gottlieb MA; Spatz ES; Yu H; Wang RC; Slovis BH; Saydah S; Plumb ID; O'Laughlin KN; Montoy JCC; McDonald SA; Lin Z; Lin JS; Koo K; Idris AH; Huebinger RM; Hill MJ; Gentile NL; Chang AM; Anderson J; Hota B; Venkatesh AK; Weinstein RA; Elmore JG; Nichol G;
JAMA Netw Open; 2022 Dec; 5(12):e2244486. PubMed ID: 36454572
[TBL] [Abstract][Full Text] [Related]
36. Rates of ICD-10 Code U09.9 Documentation and Clinical Characteristics of VA Patients With Post-COVID-19 Condition.
Wander PL; Baraff A; Fox A; Cho K; Maripuri M; Honerlaw JP; Ho YL; Dey AT; O'Hare AM; Bohnert ASB; Boyko EJ; Maciejewski ML; Viglianti E; Iwashyna TJ; Hynes DM; Osborne TF; Ioannou GN
JAMA Netw Open; 2023 Dec; 6(12):e2346783. PubMed ID: 38064215
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and Characteristics Associated With Post-COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults.
Selvakumar J; Havdal LB; Drevvatne M; Brodwall EM; Lund Berven L; Stiansen-Sonerud T; Einvik G; Leegaard TM; Tjade T; Michelsen AE; Mollnes TE; Lund-Johansen F; Holmøy T; Zetterberg H; Blennow K; Sandler CX; Cvejic E; Lloyd AR; Wyller VBB
JAMA Netw Open; 2023 Mar; 6(3):e235763. PubMed ID: 36995712
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study.
Tang F; Hammel IS; Andrew MK; Ruiz JG
Lancet Healthy Longev; 2022 Sep; 3(9):e589-e598. PubMed ID: 35935474
[TBL] [Abstract][Full Text] [Related]
39. Perceived Cognitive Deficits in Patients With Symptomatic SARS-CoV-2 and Their Association With Post-COVID-19 Condition.
Liu TC; Yoo SM; Sim MS; Motwani Y; Viswanathan N; Wenger NS
JAMA Netw Open; 2023 May; 6(5):e2311974. PubMed ID: 37145596
[TBL] [Abstract][Full Text] [Related]
40. Post-COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection.
Funk AL; Kuppermann N; Florin TA; Tancredi DJ; Xie J; Kim K; Finkelstein Y; Neuman MI; Salvadori MI; Yock-Corrales A; Breslin KA; Ambroggio L; Chaudhari PP; Bergmann KR; Gardiner MA; Nebhrajani JR; Campos C; Ahmad FA; Sartori LF; Navanandan N; Kannikeswaran N; Caperell K; Morris CR; Mintegi S; Gangoiti I; Sabhaney VJ; Plint AC; Klassen TP; Avva UR; Shah NP; Dixon AC; Lunoe MM; Becker SM; Rogers AJ; Pavlicich V; Dalziel SR; Payne DC; Malley R; Borland ML; Morrison AK; Bhatt M; Rino PB; Beneyto Ferre I; Eckerle M; Kam AJ; Chong SL; Palumbo L; Kwok MY; Cherry JC; Poonai N; Waseem M; Simon NJ; Freedman SB;
JAMA Netw Open; 2022 Jul; 5(7):e2223253. PubMed ID: 35867061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
